Metabolic progress and an ongoing lipid priority appear in the same record. See how repeated blood results can reveal both the changes and the work still to do.
N.F., male, 49, was followed from October 2025 to May 2026. HOMA-IR fell from 1.37 to 0.49, fasting insulin from 5.54 to 2.52 µIU/mL and fasting glucose from 100 to 78 mg/dL. Those paired insulin and glucose results show the metabolic trend over the seven-month period.
Different markers can need different next steps
N.F.’s fasting insulin, glucose and HOMA-IR fell, while ApoB rose and LDL stayed broadly similar. The source records a separate pharmacological addition for lipids. The useful lesson is the detail: a plan can respond to each marker instead of assuming one improvement answers every question.
Starting point and context
The case also records lower liver enzymes: ALT from 29 to 20 U/L and AST from 24 to 20 U/L. His KDM-13 score fell from 35.7 to 32.3 years, a 3.4-year change. The source uses EVA’s optimisation targets when describing the baseline HOMA-IR as borderline and the follow-up as optimal; these labels should not be treated as a standalone diagnosis.
Explore EVA blood biomarker testing
The recorded results
| Biomarker | Oct 2025 | May 2026 | Change |
|---|---|---|---|
| Metabolic | |||
| Fasting Glucose (mg/dL) | 100 | 78 | −22% |
| Fasting Insulin (µIU/mL) | 5.54 | 2.52 | −55% |
| HOMA-IR | 1.37 | 0.49 | −64% |
| Liver | |||
| ALT (U/L) | 29 | 20 | −31% |
| AST (U/L) | 24 | 20 | −17% |
| Nutrition | |||
| Vitamin D (ng/mL) | 46.8 | 52.0 | +11% |
| Vitamin B12 (pg/mL) | 706 | 906 | +28% |
| Folate (ng/mL) | 13.42 | 16.49 | +23% |
| Biological Age | |||
| KDM-13 Biological Age | 35.7 yrs | 32.3 yrs | −3.4 yrs |
Figures are reproduced from the case record, including qualitative entries and reported percentage changes. Source labels such as optimal describe the case’s interpretation, not a universal reference range. A dash indicates a value not supplied.
Context that matters
- ApoB moved from 106 to 114 mg/dL and LDL from 149.6 to 150.2 mg/dL. These did not improve alongside the metabolic markers.
- Lp(a) was reported as >240 nmol/L, above the source laboratory’s measurement ceiling. The greater-than sign is part of the result.
- The source reports an EBV/glandular fever infection at the May panel, contributing clinical context for raised CRP and lymphocytes. Exact CRP and lymphocyte values are not supplied.
- The source does not provide a complete named supplement regimen or the name and dose of the subsequently added lipid medication; neither has been reconstructed.
The recorded protocol
The source does not supply a complete supplement list or dosing schedule for this case. The named interventions and relevant clinical context are described above and below.
Learn about personalised supplements
What remained in progress
A pharmacological complement was added for the lipid profile, according to the source. This is an important part of the story: better insulin and glucose results do not mean that every cardiovascular marker has improved, or that all aspects of care can be handled with supplements.
Reading the biological-age result
Biological-age scores are model outputs derived from the inputs available to that model. A lower score is not a measured gain in lifespan. Different models use different inputs and should be labelled and interpreted separately.
Did all of N.F.’s markers improve?
No. Insulin, glucose, HOMA-IR and liver enzymes fell, while ApoB rose from 106 to 114 mg/dL and LDL stayed broadly unchanged. The lipid profile remained a separate clinical priority.
How this connects to EVA
EVA connects blood testing, clinician-reviewed personalised supplements and follow-up. Blood Intelligence uses your blood results; Elite DNA + Blood adds genetic information. DNA is optional. The aim is a personal plan grounded in your information, with review as new results become available.
Find out what your results need next
If you are looking at glucose or insulin results, a clinician-reviewed assessment can put those values alongside the rest of your blood profile.
See how to start with EVAExplore blood testing, optional DNA and personalised supplements, with the current steps to get started in Dubai.
This is an individual observational case, not a controlled trial. Biomarker changes and biological-age scores do not establish the effect of a particular supplement, predict an individual’s lifespan or guarantee future results. The protocol described was personalised and is not a recommendation to self-prescribe. EVA supports informed health decisions and is not intended to diagnose, treat, cure or prevent disease. Consult a qualified healthcare provider for medical advice.
Source: EVA clinical case record supplied for publication. Observation dates and model names are shown in the case. Prepared for web publication in October 2026.